New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...
ROCHESTER, MN – The PREVAIL study, a clinical trial evaluating the safety of the Watchman (Boston Scientific) left atrial appendage (LAA) closure device in the treatment of patients with nonvalvular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results